Real-World Experience of Imipenem–Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study)

Real-World Experience of Imipenem–Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study)

Abstract Introduction Difficult-to-treat-resistant (DTR) infections caused by Pseudomonas aeruginosa represent a global public health threat, prioritizing the search and development of new antibiotics for this microorganism. Methods We present the real-life experience of the compassionate use of imi...

Full description

Saved in:
Bibliographic Details
Main Authors: Isabel Machuca, Arantxa Dominguez, Rosario Amaya, Cristina Arjona, Irene Gracia-Ahufinger, Maravillas Carralon, Rosa Giron, Isabel Gea, Natividad De Benito, Andres Martin, Fatima Galan, Jose Antonio Martinez, Rayden Iglesias, Jaume Revuelto, Juan Jose Caston, Angela Cano, Elisa Ruiz-Arabi, Luis Martínez-Martínez, Julian Torre-Cisneros
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-11-01
Series:Infectious Diseases and Therapy
Subjects:
Pseudomonas aeruginosa
Imipenem
Cilastatin
Relebactam
Carbapenem
Resistant
Online Access:https://doi.org/10.1007/s40121-024-01077-z
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Introduction Difficult-to-treat-resistant (DTR) infections caused by Pseudomonas aeruginosa represent a global public health threat, prioritizing the search and development of new antibiotics for this microorganism. Methods We present the real-life experience of the compassionate use of imipenem/cilastatin/relebactam in a descriptive study involving 14 patients with DTR-P. aeruginosa infection and limited treatment options. Results The primary source of infection was skin and soft tissue infection, 57.1% (8/14), followed by respiratory infection-pneumonia, 28.6% (4/14). At the onset of infection, 71.4% (10/14) of patients were in the intensive care unit (ICU). All our patients had a Charlson Score of ≥ 3. Septic shock was observed in 64.3% (9/14) of patients. The median treatment duration was 15 days, and no patient experienced an adverse event that required treatment interruption. All-cause 30-day mortality was observed in 42.9% of cases (6/14), while clinical efficacy and microbiological success were observed in 64.3% (9/14). Conclusions Imipenem/cilastatin/relebactam may represent a treatment option for patients with DTR-P. aeruginosa infections, which should be validated in prospective clinical trials.
ISSN:2193-8229
2193-6382

Similar Items